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Patient satisfaction with psoriasis treatments
Callis Duffin et al. highlight the fact that treatment satisfaction among 
patients with moderate-to-severe psoriasis has not previously been 
studied and compared across treatments using a validated instru-
ment. Their aim was to assess patient-reported satisfaction with sys-
temic and phototherapy treatments for moderate-to-severe psoriasis 
in clinical practice, and to correlate satisfaction with disease severity 
and quality-of-life measures. Their study involved a cross-sectional 
analysis of 1182 patients with moderate-to-severe psoriasis in the 
Dermatology Clinical Effectiveness Research Network in the U.S.A. 
Patients receiving either topical therapies only; monotherapy with 
oral systemic therapies, biologics or narrowband ultraviolet B pho-
totherapy; or combination therapy with biologics and methotrexate 
completed version II of the Treatment Satisfaction Questionnaire for 
Medication. Their results showed that median unadjusted overall sat-
isfaction scores were highest for patients receiving biological mono-
therapies, biologic–methotrexate combinations or photo therapy 
(83.3); scores were lowest for those receiving topical therapies only 
or acitretin (66.7). In fully adjusted models, compared with patients 
receiving methotrexate monotherapy, those receiving adalimumab, 
etanercept, ustekinumab, phototherapy or adalimumab with meth-
otrexate had significantly higher median overall satisfaction scores 
by 7.2–8.3 points, while those receiving only topical therapies had 
significantly lower overall satisfaction by 8.9 points. Adjusted con-
venience scores were lowest for patients receiving topical therapies 
only or infliximab. Modest but significant correlations were found 
between overall satisfaction and Psoriasis Area and Severity Index 
(ρ = −0.36, P < 0.001) and Dermatology Life Quality Index 
(ρ = −0.47, P < 0.001). The authors concluded that discernible dif-
ferences were found for patient treatment satisfaction between 
therapies, particularly regarding treatment effectiveness and con-
venience. They stated that further application of treatment satisfac-
tion measures may inform future treatment decisions and guideline 
development. Br J Dermatol 2014; 170: 672–680.
Epigenetics, ultraviolet A1 and lichen sclerosus
The authors of this study 
explain that epigenetics 
is relevant in the patho-
genesis of autoimmune 
diseases as well as cancer. 
Their aim was to study the 
global methylation and 
hydroxymethylation status 
in vulvar lichen sclerosus 
(VLS) lesions before and 
after a 3-month course of ultraviolet (UV)A1 phototherapy treat-
ment. They studied 10 patients with VLS who were treated with 
medium-dose UVA1 four times per week for 3 months. Standard 
histology, immunohistochemistry and mutation analyses were per-
formed. Their results showed a significant (P = 0.0086) decrease in 
clinical score after UVA1 treatment, although dermal lymphocytic 
infiltrates remained unchanged in VLS (P = 0.57). Additionally, 
immunoreactivity of 5-methylcytosin was significantly (P = 0.043) 
increased in UVA1-treated VLS compared with baseline and 
controls. 5-Hydroxymethylcytosin (5hmC) was significantly 
(P = 0.0038) reduced in baseline VLS compared with controls. 
However, 5hmC immunoreactivity in UVA1-treated skin was com-
parable with that found in controls (P > 0.05). Compared with con-
trols, isocitrate dehydrogenase (IDH)1 expression was significantly 
(P = 0.0062) higher in treated and untreated VLS. IDH2 immunore-
activity was significantly (P = 0.012) reduced in baseline VLS com-
pared with controls and UVA1-treated VLS. Immunoreactivity scor-
ing for ten-eleven translocation (TET)2, p53 and p16INK4a did not 
demonstrate significant differences between the groups assessed 
(P > 0.05). Furthermore, gene sequencing of the IDH1, IDH2 and 
TET2 genes did not reveal evidence for mutations. The authors 
concluded that VLS is associated with altered expression of IDH 
enzymes and aberrant global methylation and hydroxymethylation 
patterns, indicating an epigenetic background for the patho genesis 
of VLS. Additionally, longterm UVA1 phototherapy may cause 
global DNA methylation and normalization of 5hmC patterns in 
VLS. Br J Dermatol 2014; 170: 687–693.
A novel patient-reported outcome measure to 
evaluate a novel biologic for psoriasis
Gordon et al. open this paper by 
stating that psoriasis symptoms 
have a significant negative impact 
on health-related quality of life, 
impairing physical functioning 
and well-being. The authors’ stat-
ed objective was to evaluate the 
impact of brodalumab, a human 
anti-interleukin-17 receptor 
monoclonal antibody, on psoriasis 
symptom severity as measured by 
a novel patient-reported outcome measure, the Psoriasis Symptom 
Inventory (PSI), and dermatology-specific health-related quality of 
life as measured by the Dermatology Life Quality Index (DLQI). The 
methods used were a secondary analysis of a phase 2, randomized, 
double-blind, placebo-controlled clinical study of patients with 
moderate-to-severe psoriasis treated with brodalumab or placebo. 
This analysis assessed PSI and DLQI scores over time. Analyses were 
conducted on all patients, who were randomized and received at 
least one injection of study drug according to intention-to-treat anal-
ysis using the last-observation-carried-forward method to impute 
missing data. Results at week 12 revealed that subjects in the broda-
lumab groups had significant improvements in mean PSI and DLQI 
total scores compared with placebo. Furthermore, improvements in 
PSI were observed as early as week 2 and in DLQI by week 4. All 
eight PSI item scores improved significantly among the brodalumab 
groups by week 12. The authors acknowledged the limitations of 
this study, with the results being derived from a single randomized 
clinical trial, which may not generalize to broader patient popula-
tions. They concluded that treatment with brodalumab provided sig-
nificant improvement in psoriasis symptoms and that PSI and DLQI 
score responses exhibited a dose response, distinguishing between 
brodalumab treatment and placebo, and among brodalumab dose 
regimens. Br J Dermatol 2014; 170: 705–715. 
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